Advanced Search
Contact | Corporate | Help

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Sponsors:
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Genentech
  • Protein Sciences Corporation
Phases:
  • Phase I
IndicationsAcronym:
  • HIV Infections
Age Groups:
  • Child
  • Adult
Gender:
Both
Names:
  • Biological: rgp120/HIV-1MN
  • Biological: rgp120/HIV-1 SF-2
  • Biological: gp160 Vaccine (MicroGeneSys)
Enrollment:
72

Additional information about NCT00000762.


SourceSolution © 2008-2012